A PHASE I AND PHARMACOKINETIC STUDY OF ORAL 3-AMINOPYRIDINE-2- CARBOXALDEHYDE

口服3-氨基吡啶-2-醛的I期及药代动力学研究

• 批准号: 7982131
• 负责人: HEINZ JOSEF LENZ
• 金额: $ 1.39万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982131
• 关键词: Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Kinetics; Funding; Gene Expression; Grant; Institution; Oral; Patients; Peripheral Blood Mononuclear Cell; Phase; Phase I Clinical Trials; Research; Research Personnel; Resources; Safety; Solid Neoplasm; Source; Testing; Toxic effect; Triapine; United States National Institutes of Health; alpha-aminopyridine; neoplastic cell; response; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase I study using oral Triapine to determine safety and tolerability in patients with advanced solid tumors. The MDT will be determined to recommend the dose for phase II testing by accessing toxicities to this agent. Pharmacokinetics will be done on IV and oral dose Triapine. Peripheral blood mononuclear cells will be evaluated along with gene expression in tumor cells. A secondary end point will be to access tumor response.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项I期研究，使用口服Trivalent来确定晚期实体瘤患者的安全性和耐受性。MDT将通过评估该药物的毒性来确定II期试验的推荐剂量。将对IV和口服剂量Trilazone进行药代动力学研究。将沿着评价外周血单核细胞以及肿瘤细胞中的基因表达。次要终点将是评估肿瘤反应。